PAP
CRBP icon

Persistent Asset Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Persistent Asset Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.6K Buy
+292
New +$2.46K 0.03% 246

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Persistent Asset Partners's CRBP Position: Q1 2026 in Review

Persistent Asset Partners increased its Corbus Pharmaceuticals (CRBP) stake by 1,589% in Q1 2026, buying an estimated $881K and bringing the position to 111,226 shares worth $1.04M. The position accounts for 0.39% of the portfolio, ranked #61.

Persistent Asset Partners first reported a position in CRBP in Q4 2025 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Persistent Asset Partners held 111,226 shares of Corbus Pharmaceuticals worth $1.04M as of Q1 2026.
  • Persistent Asset Partners bought 104,639 Corbus Pharmaceuticals shares in Q1 2026, an estimated $881K.
  • Corbus Pharmaceuticals made up 0.39% of Persistent Asset Partners's portfolio in Q1 2026, its #61 holding.
  • Persistent Asset Partners first reported a position in Corbus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.